Study protocol. Study protocol. Eight subjects (seven men and one woman) with type 2 diabetes entered the study. The subjects discontinued their antidiabetic.

Slides:

Advertisements

Similar presentations

Moderate Amounts of Fructose Consumption Impair Insulin Sensitivity in Healthy Young Men: A Randomized Controlled Trial Featured Article: Isabelle Aeberli,

Advertisements

Fig. 1 Schematic presentation of the metabolic actions of GH with emphasis on the direct stimulation of lipolysis and the more indirect preservation of.

Adding rosiglitazone to metformin in patients with type 2 diabetes: Effect on diabetes control and metabolic parameters Hussein Raef, Abdulraof Al-Mahfouz,

Metformin Use in Chronic Kidney Disease

Placebo Metformin ***p < vs placebo

Choosing a test of glucose metabolism in mice.

Diabetes Journal Club Julie Shah.

Volume 126, Issue 3, Pages (March 2004)

FIGURE 1 Schematic of stable-isotope infusion studies performed for the measurement of BCAA and FFA kinetics. In study protocol 1, BCAA kinetics in 14.

Study design. Study design. Each subject with or without type 2 diabetes participated in euglycemic and hypoglycemic clamp visits separated by 4–8 weeks.

Relationship between plasma glucose, insulin and glucagon levels

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

James F. List, Jean M. Whaley Kidney International

Patient flow chart: the final prospective study population consisted of 521 individuals, 113 on basal insulin and 408 on OADs. *Plausibility: height (130–230 cm),

Box plot representing the median GIRs (mg/kg/min) by CD300LG genotype during the last 30 min of the HEC. The center lines show the medians; box limits.

Fasting plasma adiponectin concentration in relation to body mass index (BMI) (A), waist circumference (B), acute insulin response (AIR) (C) and insulin.

(A) (B) Supplementary figure S1

Antidiabetic Effects of IGFBP2, a Leptin-Regulated Gene

Mean daily glucose concentration and frequency of hypoglycemia in long-term care residents with type 2 diabetes. Mean daily glucose concentration and frequency.

(A) Correlation between change in HbA1c and change in weight from baseline to week 24 in the liraglutide group. (A) Correlation between change in HbA1c.

Patient disposition. Patient disposition. AE, adverse event. *One patient died during the follow-up period. ^Four of the 12 discontinuations of treatment.

(A) Rate of achieving targets for glycated hemoglobin (HbA1c), blood pressure (BP), and lipids in all subjects and (B) prevalence of nephropathy, retinopathy,

Glucose uptake and expression of thermogenesis markers are increased in the BAT of HFD-fed NprcAKO mice. Glucose uptake and expression of thermogenesis.

(A–B) Differences in fat oxidation during the hyperinsulinemic euglycemic clamp between African–American and non-Hispanic white women after 7 days of a.

Systemic GADD45β deletion affects metabolic regulation under conditions of heightened lipid metabolism Systemic GADD45β deletion affects metabolic regulation.

Completed and ongoing CVOTs (6–14,39,44–58)

Experimental protocol for days 2, 3 and 4.

Hyperinsulinemic-euglycemic clamps revealed that obese TPL2KO mice have an improved insulin sensitivity compared with obese WT mice. Hyperinsulinemic-euglycemic.

One- to two-hour plasma glucose concentrations over a 24-hour period in patients taking maximal doses of either glyburide (20 mg/day) or glipizide (40.

Effect of metformin on glycemic control, insulin secretion, and insulin sensitivity in T2D. Effect of metformin on glycemic control, insulin secretion,

NOx ASR (in mmol/day), arginine Ra (in µmol/kg × min), the fraction of arginine flux converted to NOx (%), and the insulin-mediated glucose disposal (M)

Hyperinsulinemic-euglycemic clamp–derived insulin sensitivity (glucose disposal), model-derived insulin secretion parameters (sensitivity first-phase insulin.

Glucose metabolic index measured using 2-deoxyglucose (2[3H]DG) was measured for the gastrocnemius and superficial vastus lateralis (SVL) during the last.

Correlation between muscle Hsp-72 mRNA expression and rates of glucose and lipid turnover, as determined in protocol 2 (n = 36). Correlation between muscle.

Plasma glucose (A) and glucose specific activity (B) during euglycemic clamp experiments. Plasma glucose (A) and glucose specific activity (B) during euglycemic.

TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin resistance. TG-CRP mice display fasting hyperglycemia, hyperinsulinemia, and insulin.

Study protocol. Study protocol. Fourteen patients had research renal biopsies, and 17 patients with macroalbuminuria had renal biopsies for clinical reasons.

Glucose infusion rate required to maintain the hyperglycemic clamp during the experimental period in sedentary and exercised dogs receiving basal or elevated.

Statin Therapy in Patients With Insulin Resistance

A: The change of plasma glucose in opioid μ-receptor knockout diabetic mice and wild-type controls receiving an oral intake of metformin (100 mg/kg). A:

Effect of gonadotropin-releasing-hormone-induced hypogonadism on insulin action as assessed by euglycemic clamp studies in men Subodhsingh Chauhan, M.D.,

Left columns: Plasma glucose and serum insulin concentrations, circulating TF-PCA, and FVIIa activity before and during 24 h of selective hyperglycemia.

Sustained activation of AMPK α2 in muscle of subjects with type 2 diabetes after an overnight withdrawal of metformin. Sustained activation of AMPK α2.

The effect of sulfonylurea (glibenclamide = glyburide) and metformin therapy on the plasma HbA1c concentration in newly diagnosed T2DM subjects in UKPDS.

A: The correlation between the GIR and FGU, each measured during the last 40 min of the euglycemic insulin clamp. A: The correlation between the GIR and.

Correlation of muscle Rg' with circulating triglyceride levels and local LCACoAs content in the clamp state. Correlation of muscle Rg' with circulating.

Effects of in vivo AICAR treatment on blood glucose and lactate concentrations. Effects of in vivo AICAR treatment on blood glucose and lactate concentrations.

Phosphorylation of AMPK-Thr172 before and after metformin treatment in muscle from subjects with type 2 diabetes. Phosphorylation of AMPK-Thr172 before.

GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. GLP-1 and gastrin combination therapy restores normoglycemia in NOD mice. Beginning.

ATL-801 treatment increases insulin sensitivity in KKAY mice.

Subchronic glycemic effects after vehicle, metformin, SGLT2I, or combination treatment. Subchronic glycemic effects after vehicle, metformin, SGLT2I, or.

Effect of cold exposure on determinants of glucose tolerance.

MϕRIP140KD mice exhibit improved metabolic phenotypes.

Effects of berberine on in vivo metabolism in two animal models of insulin resistance. Effects of berberine on in vivo metabolism in two animal models.

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Metabolic effects of VSG in GLP-1r KO mice.

Plasma glucose, GIR, rates of EGP and glucose utilization, and plasma concentrations of free fatty acids (FFAs) and β-hydroxy-butyrate after a subcutaneous.

Blood glucose levels in chicken embryos.

Effect of GSK-3 inhibitors on basal and insulin-stimulated glucose uptake in human muscle cells. Effect of GSK-3 inhibitors on basal and insulin-stimulated.

Effects of rhein on FBG (A) and glucose intolerance (B) in db/db mice.

Metabolic parameters in the three groups of patients during l-arginine infusion. Metabolic parameters in the three groups of patients during l-arginine.

Effect of empagliflozin on efficacy parameters at week 18.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Study design (A) and patient disposition (B).

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

Clinical responses to therapy from baseline to week 24 and end point with last observation carried forward (LOCF). Clinical responses to therapy from baseline.

Distribution of daily frequency of BGM

Spearman rank order correlation between suppression of hepatic glucose production with low insulin infusion and 30-min change in glucose response in women.

Glycemic control in Hispanic and non-Hispanic patients during the SWITCH 2 trial. Glycemic control in Hispanic and non-Hispanic patients during the SWITCH.

Insulin secretion (hyperglycemic clamp) (A), insulin sensitivity (hyperinsulinemic-euglycemic clamp) (B), and glucose disposition index (GDI) (C) in adolescents.

Presentation transcript:

Study protocol. Study protocol. Eight subjects (seven men and one woman) with type 2 diabetes entered the study. The subjects discontinued their antidiabetic therapy during a 3-week washout period. They underwent blood sampling for determination of glucose, insulin, HbA1c, free fatty acids, lactate, and lipids. This was immediately followed by an initial vastus lateralis muscle biopsy as described in research design and methods. After the muscle biopsy, glucose turnover measurements and indirect calorimetry were performed during a hyperinsulinemic-euglycemic clamp as described in research design and methods. The subjects then started metformin orally at 500 mg/day, and the dose was increased weekly by 500 mg/day to a maximal of 1 g twice a day. After 4 weeks of treatment (1 week on maximal treatment), a second biopsy was done (4-week biopsy). Subjects continued on the maximal dose for 6 more weeks, and a third biopsy was done (10-week biopsy) immediately after blood sampling for the same metabolic parameters examined at the time of the first biopsy. Immediately after the 10-week biopsy, glucose turnover measurements and indirect calorimetry were performed during another clamp. Six subjects continued maximal dose treatment and underwent a final biopsy within 1 week of the 10-week biopsy but after withholding metformin overnight (withdrawal). Nicolas Musi et al. Diabetes 2002;51:2074-2081 ©2002 by American Diabetes Association